title: Efficacy and safety of combination therapy of high-dose losartan and hydrochlorothiazide in patients with hypertension.
abstract: OBJECTIVE
  We analyzed the efficacy and safety of combination therapy of high-dose losartan (100 mg/day) and hydrochlorothiazide (HCTZ, 12.5 mg/day) compared with those of the combination of high-dose telmisartan (80 mg/day) and HCTZ (12.5 mg/day).
  
  
  METHODS
  Forty hypertensive patients who received a combination of high-dose telmisartan and HCTZ were enrolled. We applied a changeover strategy with switching from a combination of high-dose telmisartan and HCTZ to high-dose losartan and HCTZ. We divided the patients into two groups; those who achieved the target blood pressure (controlled group) and those who did not reach the target blood pressure (uncontrolled group) before the changeover and performed further analysis.
  
  
  RESULTS
  The uncontrolled group showed a significant decrease in systolic blood pressure (SBP) (143±12 mmHg to 126±11 mmHg at three months). In addition, serum uric acid significantly decreased in all subjects, and in each of the controlled and uncontrolled groups. There were no significant changes in other biochemical parameters, such as potassium and hemoglobin A1c, at three months after the changeover in all subjects.
  
  
  CONCLUSIONS
  Combination therapy with high-dose losartan and HCTZ was superior to the combination of telmisartan and HCTZ with respect to significant decreases in systolic blood pressure and serum uric acid in hypertensive patients.
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan Inoue Hospital, Fukuoka, Japan Shirotani Hospital, Fukuoka, Japan Fujisawa Clinic, Fukuoka, Japan.
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Shiga
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Japan miuras@cis.fukuoka-u.ac.jp.
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Miura
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Norimatsu
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan Inoue Hospital, Fukuoka, Japan.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Hitaka
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan Matsunaga Hospital, Fukuoka, Japan.
authors.forename: Itsuki
authors.initials: I
authors.lastname: Nagata
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan.
authors.forename: Rie
authors.initials: R
authors.lastname: Koyoshi
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan Matsunaga Hospital, Fukuoka, Japan.
authors.forename: Joji
authors.initials: J
authors.lastname: Morii
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kuwano
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Japan.
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Uehara
authors.affiliation: Inoue Hospital, Fukuoka, Japan.
authors.forename: Asao
authors.initials: A
authors.lastname: Inoue
authors.affiliation: Shirotani Hospital, Fukuoka, Japan.
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Shirotani
authors.affiliation: Fujisawa Clinic, Fukuoka, Japan.
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Fujisawa
authors.affiliation: Matsunaga Hospital, Fukuoka, Japan.
authors.forename: Eiyu
authors.initials: E
authors.lastname: Matsunaga
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Japan Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Japan.
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000652:urine; D003971:Diastole / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D019808:Losartan / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D011188:Potassium / Q000097:blood; D013599:Systole / Q000187:drug effects; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood / Q000652:urine
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D003404:Creatinine; D006442:Glycated Hemoglobin; D006852:Hydrochlorothiazide; D019808:Losartan; D011188:Potassium; D014527:Uric Acid
keywords: Blood pressure; angiotensin II type 1 receptor blocker; hydrochlorothiazide; losartan; uric acid